Tripartite meeting held between the EMA, FDA and PMDA at the EMA, London, on 1-2 September 2016 to discuss regulatory approaches for the evaluation of antibacterial agents The EMA, FDA and PMDA consider that a robust response to the problem of antimicrobial resistance must be multi-facetted and that the regulatory approach for the evaluation of antibacterial agents is only one element of the total response that is required to encourage and accelerate new antibacterial drug development to meet patient needs. These three regulatory agencies recognize that:
It is appropriate to exercise flexibility with regard to the requirements for clinical development programmes for antibacterial agents, especially for new agents that may be used to treat patients with limited treatment options because of antimicrobial resistance;
There is benefit in further convergence on the data requirements for the approval of antibacterial agents;
It may be appropriate to accept a greater degree of uncertainty regarding the benefit-risk balance when developing new antibacterial agents that can be used to treat patients with limited treatment options, e.g. it may be acceptable to conduct trials in smaller numbers of patients than would usually be required;
It is important to conduct sound analyses of the pharmacokinetic-pharmacodynamic relationship for the purposes of selecting dose regimens for study in clinical trials, including regimens that may minimize the risk of selecting for resistant organisms;
There is value in developing clinical trial networks to facilitate the evaluation of new antibacterial agents and the development of such networks is encouraged;
There is value in continuing the discussions that were initiated 1-2 September 2016 at the EMA; further discussions proposed for Spring 2017 will take into account not only the pre-approval clinical development programmes but also activities conducted in the post-approval period.
See websites for contact details U.S. Food and Drug Administration: www.fda.gov European Medicines Agency: www.ema.europa.eu Pharmaceuticals and Medical Devices Agency: www.pmda.go.jp
Tripartite meeting held between the EMA, FDA and PMDA at the EMA ...
Sep 7, 2016 - European Medicines Agency: www.ema.europa.eu ... further discussions proposed for Spring 2017 will take into account not only the pre- ...
Oct 19, 2016 - network. Mark Turner. For information 10'. 16:25 Update on emerging networks outside EU. Mark Turner. For information 5'. 16:35 Enpr-EMA contribution to public consultation on the reflection paper on the use of extrapolation in the dev
Legislation in the European Union harmonises the test requirements between Member States, to ensure a consistently high level of public-health protection ..... Data protection. The purpose of processing of the data you submit is to manage your applic
Sep 26, 2016 - Support for medicines development and market access ... the application process (application form) for direct involvement in EMA activities ...
Jul 30, 1974 - plifying the handling, storage, shipping, installation and removal. ... holes progressively closer to each other toward the remote end of the hose ...
Dec 15, 2016 - Refine efforts in the domain of information on medicines to ... Share best practices on how healthcare professionals' organisations are creating ...
Minutes EMA â Payer Community meeting. 19 September 2017, 10.00-16.00 BST ... Payer Community: Ad Schuurman (am) / Menno Aarnout (pm). EMA: Harald Enzmann (am) ... beneficial medicines and to address some of the inefficiencies of the current system
of marketing-authorisation applications or matters referred to its committees. Page 3 of 13. About-EMA-English.pdf. About-EMA-English.pdf. Open. Extract.
Dec 14, 2017 - Workload estimations are based on the information provided in the official Agency's Work Programme. At the beginning of each year the financial compensation/remuneration is calculated taking into account the workload as forecasted for
Jun 13, 2018 - Page 2/7. Background. On 13 June 2018, the European Medicines Agency ... Page 3/7 and active pursuits or even carry out daily tasks such as ...
Nov 15, 2016 - conference window. Please ensure ... full international format and click Join to receive a call from the system (you will be automatically muted).
Nov 9, 2017 - EMA should explore possibilities for further engagement with academia on the subject of efficacy of veterinary vaccines within the Framework ...
authorisation application to EMA. Each new medicine is ... EMA encourages research and development of new ... in the EU, we have access to the best scientific.
There was a problem previewing this document. Retrying... Download. Connect more apps... Try one of the apps below to open or edit this item. EMA Report ...